1. Владимирская Е.Б. Механизмы кроветворения и лейкемогенеза. 2007. М.: Династия.
2. Масчан А.А., Самочатова Е.И. Применение гранулоцитарного колониестимулирующего фактора в детской гематологии/онкологии. Вопр. гематол., онкол. и иммунол. в педиатр. 2006; 5(1): 3–9.
3. Райкина Е.В. Механизмы мобилизации клеток крови под действием гранулоцитарного колониестимулирующего фактора. Дис... канд. мед. наук. М., 2007.
4. Финогенова Н.А. Дифференциальный диагноз и тактика лечения нейтропений у детей. Дис... д-ра мед. наук. М., 1999.
5. Blaise D, Kuentz M, Fortanier C et al. Randomized trial of bone marrow versus legrastim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Society Francaise de Greffe de Motlle. J Clin Oncol 2000; 18: 537–46.
6. Bolwell B, Goormastic M, Dannley R et al. G-CSF pos-autologous progenitor cell transplantation: a randomized study of 5, 10 and 16 mcg/kg/dae. Done Marrow Transplant 1997; 19(3): 215–9.
7. Dale DC. G-CSF in chronic neutropenia. Oncol Rew 1991; 6 (4): (4–5).
8. Donadio J, Leblanc T, Bader Meunier B et al. Analysis of risk factors for myelodysplasias, leukemias and death from infertion among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Grouh. Haematologica 2005; 90 (1): 45–53.
9. Fourcade M. Human recombinant granulocyte coliny stimulating factors: Glycosylation makes the difference. La Presse Medicale 1997; 26 (30).
10. Germeschausen M, Schulze H, Kratz C et al. An acquired G-CSF receptor mutation results in increased proliferation of CMML cells from a patient with severe congenital neutropenia. Leukemia 2005; 19 (4): 611–7.
11. Gluckman E, Rokicka-Milewska R, Hann I et al. Results and follow-up of a phase 111 randomized study of recombinant human-granulocyte stimulation factor for immunosuppressive therapy in patients with severe aplastic anemia. Brit J Haematology 2002; 119: 1075–82.
12. Heath JA, Steinhers PG, Altman A et al. Human granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a Children's Cancer Group Study. J Clin Oncol 2003; 21 (8): 1612–7.
13. Herbst A, Koester M, Wirth D et al. G-CSF receptor mutations in patients with severe congenital neutropenia do not abrogate Jak2 activation and stat 1/stat3 translocation. Ann N Y Acad Sci 1999; 872 (5): 325–7.
14. Hoglund M, Smerdmyr B, Bengtsson V et al. Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers: a comparative study. Eur J Haematology 1997; 59: 177–83.
15. Juan O, Campos JM, Caranana V et al. A randomized, crossover comparison of dose standard-dose versus Low-dose lenograstin in the prophylaxis of post-chemotherapy neutropenia. Support Care Cancer 2001; 9 (4): 241–6.
16. Kojimo S, Hibi S, Kassaka Y et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine and danasol with acquired aplastic anemia. Blood 2000; 96 (6): 1931–4.
17. Kroger N, Renger H, Kruger W et al. A randomized comparetion of once versus twice daily recombinant human dranulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for transplantation. Br J Haematol 2000; 111 (3): 761–5.
18. Locasciull A. Results clarify the merits of treatment options for aplastic anemia. Haematology insight. Reports from the American Society of Hematology 48th Annual Meeting. December 9–12. 2006. Orlando, USA.
19. Michel G, Landman-Parker J, Auclerc MF et al. use recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18 (7): 1517–24.
20. Moore M, Melcalf D. Haemopoietic colinies, Berlin, Heidelberg New York: Springer-Verlag. 1977.
21. Smith TJ (Chair), Khatcheressian J, Lyman G et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Cased Clinical Practice Guideline. J Clin Oncology 2006; 24 (1): 3187–205.
22. Suh C, Kim HJ, Kim SH et al. Low-dose lenograstim to engraftment after autologous strem cell transplantation: a prospective randomized evolution of two different fixed doses. Transfusion 2004; 44 (4): 533–8.
23. Toner GC, Shapiro JD, Laidlaw CR et al. Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison. J Clin Oncol 1998; 16 (12): 3874–9.
24. Ward A, van Aesch YM, Schelen AM et al. Defective intercanalization and sustained activation of truncated granulocyte colonystimulating factor receptor found in sever congenital neutropenia/acute myeloid leukemia. Blood 1999; 93 (2): 447–58.
25. Watts M, Addison SG, Long S et al. Crossover study of the haematologycal effects and pharmacokinetics of glycosylated and nonglycosylated G-CSF in healthy volunteers. Brit J Haematology 1997; 98: 474–9.
26. Welte K, Box LA Severe chronic neutropenia: pathophysiology and therapy. Semin Hematol 1997; 43 (4): 267–78.
27. Welte K, Reiter A, Mempel R et al. A randomized phase-111 study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group Bool 1996; 87 (8): 3143–50.

Н.А.Финогенова

ФГУ ФНПЦ детской гематологии, онкологии и иммунологии Росздрава